Experienced in Peripheral Neuropathy

Dominic Mulindwa-Kaddu

Kirrberger Str. 100, 
Homburg, SL, DE 
Experienced in Peripheral Neuropathy
Kirrberger Str. 100, 
Homburg, SL, DE 
OverviewLocationsClinical Research

Overview

Dominic Mulindwa-Kaddu practices in Homburg, Germany. Mr. Mulindwa-Kaddu is rated as an Experienced expert by MediFind in the treatment of Peripheral Neuropathy. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Peripheral Neuropathy.

Gender
Male

Locations

Kirrberger Str. 100, Homburg, SL 66421, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Cytarabine, Daunorubicin, Idarubicin
Study Phase: Phase 3

45 Total Publications

Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
Journal: International journal of molecular sciences
Published: October 19, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mulindwa-Kaddu's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile